<DOC>
	<DOCNO>NCT00912925</DOCNO>
	<brief_summary>This study conduct demonstrate safety clinical efficacy Aldurazyme treatment MPS I patient</brief_summary>
	<brief_title>Clinical Study Aldurazyme Patients With Mucopolysaccharidosis ( MPS ) I</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>The patient document diagnosis MPS I confirm measurable clinical sign symptom MPS I fibroblast leukocyte alphaLiduronidase enzyme activity level le 10 % low limit normal range measure laboratory . Female patient childbearing potential negative pregnancy test ( urinebetahuman chorionic gonadotropin ( hCG ) ) baseline ( female patient childbearing potential sexually mature male patient advise use medically accepted method contraception throughout study ) . The patient capable stand independently 6 minute walk minimum 5 meter within 6 minute . The patient capable perform reproducible FVC maneuver . The patient baseline FVC value less equal 80 % patient 's predict normal FVC value base polgar predict value stand height child 5 7 year age Hankinson predict value age 8 . The patient undergone tracheostomy . The patient previously undergone bone marrow transplantation . The patient pregnant lactating . The patient receive investigational drug within 30 day prior study enrollment . The patient medical condition , serious intercurrent illness , extenuate circumstance could significantly interfere study compliance include prescribe evaluation followup activity . The patient know hypersensitivity rhIDU component active placebo test solution .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>